{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T04:46:16Z","timestamp":1782794776536,"version":"3.54.5"},"reference-count":77,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Ipilimumab, a cytotoxic T-lymphocyte associated antigen-4 inhibitor, is associated with immune-related endocrine adverse events, among which hypophysitis represents a distinctive but incompletely characterized toxicity. This study aimed to systematically summarize the clinical characteristics, therapeutic approaches, and prognostic outcomes of ipilimumab-induced hypophysitis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective, case-based synthesis of ipilimumab-induced hypophysitis. PubMed, EMBASE, Web of Science, WanFang Data, and CNKI were systematically searched from database inception to February 1, 2026, to identify eligible case reports and case series using combinations of terms related to ipilimumab, hypophysitis, and immune-related adverse events. The methodological quality of included reports was assessed using the Joanna Briggs Institute Critical Appraisal Checklist.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 76 patients were included. The median age was 58 years (range 26\u201382), and 61.8% were male. The median time to onset was 9 weeks (range 1.6\u201337), with more than half occurring within the first 10 weeks of treatment. Headache (68.0%) and fatigue (64.0%) were the most common symptoms. Secondary adrenal insufficiency predominated, with low cortisol and ACTH levels detected in 93.4% and 89.8% of evaluated patients, respectively. Central hypothyroidism and hypogonadism were also frequent. Pituitary enlargement was observed in 71.0% of patients undergoing magnetic resonance imaging. Glucocorticoid replacement constituted the primary treatment. Clinical improvement occurred in 82.9% of patients; however, persistent endocrine dysfunction remained common, and complete hormonal recovery was rare (7.9%). Ipilimumab rechallenge was uncommon. According to the WHO\u2013UMC system, most cases (80.3%) were classified as probable.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Ipilimumab-induced hypophysitis typically occurs early in treatment and is characterized by secondary adrenal insufficiency with frequent pituitary enlargement. Although symptoms often improve with hormone replacement, recovery of pituitary function is uncommon, warranting long-term endocrine monitoring.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1828090","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T04:25:06Z","timestamp":1782793506000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical characteristics, management, and prognosis of ipilimumab-induced hypophysitis: a retrospective analysis of 76 cases"],"prefix":"10.3389","volume":"17","author":[{"given":"Ling","family":"Wu","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Zhuzhou Hospital Affiliated to Xiangya School of Medicine, Central South University","place":["Zhuzhou, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuping","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Zhuzhou Hospital Affiliated to Xiangya School of Medicine, Central South University","place":["Zhuzhou, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiongli","family":"Su","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Zhuzhou Hospital Affiliated to Xiangya School of Medicine, Central South University","place":["Zhuzhou, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-021-00345-8","article-title":"The foundations of immune checkpoint blockade and the ipilimumab approval decennial","volume":"21","author":"Korman","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"B3","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1186\/s12967-020-02588-2","article-title":"Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis","volume":"18","author":"Marchetti","year":"2020","journal-title":"J Transl Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2020.1826436","article-title":"Ipilimumab: an investigational immunotherapy for glioblastoma","volume":"29","author":"Youssef","year":"2020","journal-title":"Expert Opin Investig Drugs"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2025.2543510","article-title":"Immune-related hepatitis and hypophysitis are associated with superior survival in melanoma patients treated with combined ipilimumab and nivolumab","volume":"14","author":"Al Remawi","year":"2025","journal-title":"Oncoimmunology"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1155\/crom\/3517328","article-title":"Immune checkpoint inhibitor-mediated aseptic meningitis and hypophysitis","volume":"2025","author":"Bleik","year":"2025","journal-title":"Case Rep Oncol Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1080\/1120009x.2024.2359838","article-title":"Elevated ck from immune checkpoint inhibitor- related hypophysitis: a case report","volume":"37","author":"Gill","year":"2025","journal-title":"J Chemother"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1080\/1750743x.2025.2604430","article-title":"Multisystem immune-related adverse events during combined ipilimumab-nivolumab with subsequent disease progression: a case report","volume":"17","author":"Jonsdottir","year":"2025","journal-title":"Immunotherapy"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-015-0301-z","article-title":"Ipilimumab-induced hypophysitis: review of the literature","volume":"38","author":"Araujo","year":"2015","journal-title":"J Endocrinol Invest"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.98717","article-title":"Immune checkpoint inhibitor-related hypophysitis and pituitary dysfunction: a systematic review of diagnosis and management","volume":"17","author":"SirDeshpande","year":"2025","journal-title":"Cureus"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.2147\/cmar.S224791","article-title":"Managing ipilimumab-induced hypophysitis: challenges and current therapeutic strategies","volume":"12","author":"Tsoli","year":"2020","journal-title":"Cancer Manag Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003844","article-title":"Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b\/4 checkmate 920 trial","volume":"10","author":"Tykodi","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-021-00484-3","article-title":"Endocrine toxicities of immune checkpoint inhibitors","volume":"17","author":"Wright","year":"2021","journal-title":"Nat Rev Endocrinol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1055\/s-0034-1369961","article-title":"Endocrinologic side effects of oncologic treatment with anti-ctla-4-antibodies","volume":"139","author":"Fischli","year":"2014","journal-title":"Dtsch Med Wochenschr"},{"key":"B15","doi-asserted-by":"publisher","first-page":"66","DOI":"10.3390\/medicina58030336","article-title":"A pathological complete response to the combination of ipilimumab and nivolumab in a patient with metastatic renal cell carcinoma","volume":"58","author":"Studentova","year":"2022","journal-title":"Med (Kaunas)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.5001","article-title":"A rare case of ipilimumab-induced reversible hypophysitis and permanent primary hypothyroidism","volume":"11","author":"Erra","year":"2019","journal-title":"Cureus"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.14310\/horm.2002.1656","article-title":"A case of multiple immune toxicities from ipilimumab and pembrolizumab treatment","volume":"15","author":"Humayun","year":"2016","journal-title":"Hormones (Athens)"},{"key":"B18","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s40425-016-0170-9","article-title":"Acute visual loss after ipilimumab treatment for metastatic melanoma","volume":"4","author":"Wilson","year":"2016","journal-title":"J Immunother Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.4158\/accr-2019-0585","article-title":"A common pituitary autoantibody in two patients with immune checkpoint inhibitor-mediated hypophysitis: zcchc8","volume":"6","author":"Leiter","year":"2020","journal-title":"AACE Clin Case Rep"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3174\/ajnr.A1623","article-title":"Ipilimumab-induced hypophysitis: mr imaging findings","volume":"30","author":"Carpenter","year":"2009","journal-title":"AJNR Am J Neuroradiol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s11102-009-0193-z","article-title":"Anti-ctla-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes","volume":"13","author":"Dillard","year":"2010","journal-title":"Pituitary"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1177\/1078155220910202","article-title":"Autoimmune hypophysitis secondary to therapy with immune checkpoint inhibitors: four cases describing the clinical heterogeneity of central endocrine dysfunction","volume":"26","author":"Hartmann","year":"2020","journal-title":"J Oncol Pharm Pract"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(17)30577-6","article-title":"Autoimmune hypophysitis","volume":"19","author":"Ileana-Dumbrava","year":"2018","journal-title":"Lancet Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13692","article-title":"Case of metastatic uveal melanoma in which an antitumor effect appeared after ipilimumab discontinuation due to autoimmune hypophysitis","volume":"44","author":"Ohnuma","year":"2017","journal-title":"J Dermatol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1199282","article-title":"Case report: imaging immune checkpoint inhibitor-induced yin-yang effects in the brain","volume":"14","author":"Bol","year":"2023","journal-title":"Front Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.582394","article-title":"Case report: ipilimumab-induced panhypophysitis: an infrequent occurrence and literature review","volume":"10","author":"Barnabei","year":"2020","journal-title":"Front Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-017-4135-6","article-title":"Checkpoint inhibitor-associated hypophysitis","volume":"33","author":"Chang","year":"2018","journal-title":"J Gen Intern Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2019.100508","article-title":"Combination checkpoint inhibitor therapy induces multiple immune major related adverse events in the treatment of vaginal melanoma: a cautionary case report","volume":"30","author":"Norwood","year":"2019","journal-title":"Gynecol Oncol Rep"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1210\/jcemcr\/luaf194","article-title":"Concomitant immune checkpoint inhibitors induced central and primary adrenal insufficiency: a diagnostic challenge","volume":"3","author":"Nasc\u00e8","year":"2025","journal-title":"JCEM Case Rep"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.89689","article-title":"Concurrent thyroiditis and hypophysitis in a patient receiving dual immune checkpoint inhibitor therapy for metastatic melanoma","volume":"17","author":"Darapu","year":"2025","journal-title":"Cureus"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.12348","article-title":"Early recognition of ipilimumab-related autoimmune hypophysitis in patients with metastatic melanoma: case studies and recommendations for management","volume":"11","author":"Tiu","year":"2015","journal-title":"Asia Pac J Clin Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2016.02.006","article-title":"Headache in a patient with renal cell carcinoma","volume":"32","author":"Subbiah","year":"2016","journal-title":"Eur J Intern Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0b013e3182639765","article-title":"Detection of early onset of hypophysitis by (18)f-fdg pet-ct in a patient with advanced stage melanoma treated with ipilimumab","volume":"38","author":"van der Hiel","year":"2013","journal-title":"Clin Nucl Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.6611","article-title":"Headache in the setting of immunotherapy treatment for metastatic melanoma","volume":"3","author":"Comstock","year":"2017","journal-title":"JAMA Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.24291","article-title":"Early detection of immune-mediated hypophysitis with use of checkpoint inhibitor immunotherapy","volume":"14","author":"Yossef","year":"2022","journal-title":"Cureus"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.20344\/amp.6541","article-title":"Ipilimumab-induced autoimmune hypophysitis: diagnostic and management challenges illustrated by a clinical case","volume":"28","author":"Marques","year":"2015","journal-title":"Acta Med Port"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-010-9794-7","article-title":"Hyponatremia associated with ipilimumab-induced hypophysitis","volume":"29","author":"Barnard","year":"2012","journal-title":"Med Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1055\/s-0033-1355337","article-title":"Hypophysitis caused by ipilimumab in cancer patients: hormone replacement or immunosuppressive therapy","volume":"121","author":"Lammert","year":"2013","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.eucr.2021.101661","article-title":"Hypophysitis induced by ipilimumab and nivolumab combination therapy for advanced renal cell carcinoma: a case report","volume":"38","author":"Motonaga","year":"2021","journal-title":"Urol Case Rep"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2023-258701","article-title":"Immune checkpoint inhibitor-induced hypophysitis with transient acth-dependent hypercortisolism","volume":"17","author":"AlRubaish","year":"2024","journal-title":"BMJ Case Rep"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.16538","article-title":"Immunotherapy-induced anterior hypophysitis","volume":"13","author":"Pachika","year":"2021","journal-title":"Cureus"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1177\/1078155217727142","article-title":"Immunotherapy-induced autoimmune hypophysitis","volume":"25","author":"Valecha","year":"2019","journal-title":"J Oncol Pharm Pract"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1530\/eje-12-0167","article-title":"Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review","volume":"167","author":"Juszczak","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"B44","article-title":"Ipilimumab immune-related adverse reactions: a case report","volume":"66","author":"Anderson","year":"2013","journal-title":"S D Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.radcr.2018.03.011","article-title":"Ipilimumab cystic hypophysitis mimicking metastatic melanoma","volume":"13","author":"Wallace","year":"2018","journal-title":"Radiol Case Rep"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-014-0199-9","article-title":"Ipilimumab, not just another anti-cancer therapy: hypophysitis as side effect illustrated by four case-reports","volume":"47","author":"Marlier","year":"2014","journal-title":"Endocrine"},{"key":"B47","doi-asserted-by":"publisher","first-page":"66","DOI":"10.5334\/jbsr.2161","article-title":"Ipilimumab (immune checkpoint inhibitors) hypophysitis","volume":"104","author":"Stagnetto","year":"2020","journal-title":"J Belg Soc Radiol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.36518\/2689-0216.1220","article-title":"Induction of hypopituitarism following ipilimumab\/nivolumab therapy followed by radiation in the treatment of metastatic scalp melanoma","volume":"2","author":"Salabei","year":"2021","journal-title":"HCA Healthc J Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1080\/01658107.2017.1368090","article-title":"Ipilimumab-induced adenohypophysitis and orbital apex syndrome: importance of early diagnosis and management","volume":"42","author":"Hassanzadeh","year":"2018","journal-title":"Neuroophthalmology"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.13604","article-title":"Onset of fulminant type\u20091 diabetes mellitus following hypophysitis after discontinuation of combined immunotherapy. a case report","volume":"12","author":"Boswell","year":"2021","journal-title":"J Diabetes Investig"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.4103\/0028-3886.198182","article-title":"Ipilimumab-induced hypophysitis and ileocolitis: Serial pituitary mri findings","volume":"65","author":"Singh","year":"2017","journal-title":"Neurol India"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2014.0105","article-title":"Ipilimumab-induced hypophysitis and uveitis in a patient with metastatic melanoma and a history of ipilimumab-induced skin rash","volume":"12","author":"Nallapaneni","year":"2014","journal-title":"J Natl Compr Canc Netw"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.radcr.2017.11.007","article-title":"Ipilimumab-induced hypophysitis involving the optic tracts and tuber cinereum evaluated using 3d fluid-attenuated inversion recovery","volume":"13","author":"Tanaka","year":"2018","journal-title":"Radiol Case Rep"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.5694\/mja14.00803","article-title":"Ipilimumab-induced hypophysitis: Early Australian experience","volume":"201","author":"De Sousa","year":"2014","journal-title":"Med J Aust"},{"key":"B55","doi-asserted-by":"publisher","first-page":"854","DOI":"10.4158\/ep-2017-0249","article-title":"Ipilimumab-induced secondary hypophysitis","volume":"24","author":"Cheema","year":"2018","journal-title":"Endocr Pract"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw255","article-title":"Ipilimumab-related hypophysitis may precede severe cns immune attack","volume":"27","author":"K\u00f6essler","year":"2016","journal-title":"Ann Oncol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.2537","article-title":"Melanoma and a headache. Diagnosis: hypophysitis","volume":"1","author":"Johnson","year":"2015","journal-title":"JAMA Oncol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12902-021-00693-x","article-title":"Multiple endocrinopathies, hypercalcaemia and pancreatitis following combined immune checkpoint inhibitor use- case report and review of literature","volume":"21","author":"Newman","year":"2021","journal-title":"BMC Endocr Disord"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.801924","article-title":"Nivolumab combined with ipilimumab treatment induced hypophysitis and immune-mediated liver injury in advanced esophageal squamous cell carcinoma: A case report","volume":"12","author":"Feng","year":"2022","journal-title":"Front Oncol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.currproblcancer.2020.100644","article-title":"Magnetic resonance imaging criteria of immune checkpoint inhibitor-induced hypophysitis","volume":"45","author":"Nada","year":"2021","journal-title":"Curr Probl Cancer"},{"key":"B61","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1186\/s40425-019-0729-3","article-title":"Recovery from secondary adrenal insufficiency in a patient with immune checkpoint inhibitor therapy induced hypophysitis","volume":"7","author":"Thapi","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.currproblcancer.2021.100710","article-title":"Pituitary enlargement following ipilimumab without long term endocrine dysfunction","volume":"45","author":"Nogueira","year":"2021","journal-title":"Curr Probl Cancer"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1097\/cmr.0000000000000517","article-title":"Refractory hypotension with fever revealing checkpoint inhibitor-induced hypophysitis","volume":"29","author":"Pla\u00e7ais","year":"2019","journal-title":"Melanoma Res"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyac220","article-title":"Recurrence of hypophysitis after immune checkpoint inhibitor rechallenge","volume":"27","author":"Park","year":"2022","journal-title":"Oncologist"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2021-241981","article-title":"Silent, isolated acth deficiency in Malignant melanoma patients treated with immune checkpoint inhibitors","volume":"14","author":"Heck","year":"2021","journal-title":"BMJ Case Rep"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.60.1807","article-title":"Swinging for the fences: Long-term survival with ipilimumab in metastatic melanoma","volume":"33","author":"Gibney","year":"2015","journal-title":"J Clin Oncol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1097\/cmr.0000000000000405","article-title":"Transient pituitary acth-dependent cushing syndrome caused by an immune checkpoint inhibitor combination","volume":"27","author":"Lupu","year":"2017","journal-title":"Melanoma Res"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.11817\/j.issn.1672-7347.2024.230536","article-title":"Hypophysitis associated with immune check piont inhibitors treatment: A case report and literature review","volume":"49","author":"Wei","year":"2024","journal-title":"Zhong Nan Da Xue Xue Bao Yi Xue Ban"},{"key":"B69","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1210\/er.2018-00006","article-title":"Endocrine toxicity of cancer immunotherapy targeting immune checkpoints","volume":"40","author":"Chang","year":"2019","journal-title":"Endocr Rev"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-018-0866-6","article-title":"Fall in thyroid stimulating hormone (tsh) may be an early marker of ipilimumab-induced hypophysitis","volume":"21","author":"De Sousa","year":"2018","journal-title":"Pituitary"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.annemergmed.2016.03.048","article-title":"Pituitary dysfunction: A case series of immune checkpoint inhibitor-related hypophysitis in an emergency department","volume":"68","author":"Miller","year":"2016","journal-title":"Ann Emerg Med"},{"key":"B72","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ctrv.2016.02.001","article-title":"Management of toxicities of immune checkpoint inhibitors","volume":"44","author":"Spain","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad260","article-title":"Clinical characters and influence factors of immune checkpoint inhibitor-related thyroid dysfunction","volume":"108","author":"Zhang","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2023.09.004","article-title":"Severe vs nonsevere immune checkpoint inhibitor-induced myocarditis: Contemporary 1-year outcomes","volume":"5","author":"Itzhaki Ben Zadok","year":"2023","journal-title":"JACC CardioOncol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1097\/coc.0000000000000239","article-title":"Ctla-4 and pd-1 pathways: Similarities, differences, and implications of their inhibition","volume":"39","author":"Elizabeth","year":"2015","journal-title":"Am J Clin Oncol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.730320","article-title":"Safety and efficacy of the rechallenge of immune checkpoint inhibitors after immune-related adverse events in patients with cancer: A systemic review and meta-analysis","volume":"12","author":"Qing","year":"2021","journal-title":"Front Immunol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1530\/EC-25-0697","article-title":"A systematic review of ipilimumab-induced hypophysitis","volume":"15","author":"Kim","year":"2026","journal-title":"Endocr Connect"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1828090\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T04:25:09Z","timestamp":1782793509000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1828090\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":77,"alternative-id":["10.3389\/fendo.2026.1828090"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1828090","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,30]]},"article-number":"1828090"}}